priors.science/reviews/chronic-kidney-disease-management

Chronic Kidney Disease Management

The current evidence on 51 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

51claims tracked
106primary papers reviewed
2 Jun 2026latest evidence review
Weeklyre-scored against new papers
11 Established · 27 Likely · 13 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
SignalClaimStandingEvidence certaintyCorpus
StablePhosphate binders reduce serum phosphateCKD MBDEstablished94%11
StableErythropoiesis-stimulating agents increase haemoglobin in chronic kidney diseaseAnaemia CKDEstablished93%10
StableCalcimimetics reduce parathyroid hormone in chronic kidney disease-mineral and bone disorderCKD MBDEstablished92%11
StableAngiotensin-converting enzyme inhibitors slow chronic kidney disease in proteinuriaRaas BlockadeEstablished92%10
StableSGLT2 composite kidney outcomes in chronic kidney diseaseSglt2 CKDEstablished91%15
StableAngiotensin receptor blockers slow chronic kidney disease in diabetic nephropathyRaas BlockadeEstablished90%10
StableHigh haemoglobin targets with erythropoiesis-stimulating agents raise cardiovascular risk in chronic kidney diseaseAnaemia CKDEstablished89%10
StableHigh FGF-23 predicts cardiovascular mortality in chronic kidney diseaseCKD MBDEstablished88%11
StableSemaglutide slows chronic kidney disease progressionGlp1 CKDEstablished88%10
StableSGLT2 reduces albuminuria in chronic kidney diseaseSglt2 CKDEstablished87%12
StableSGLT2: heart failure hospitalisation in chronic kidney diseaseSglt2 CKDEstablished86%12
StableHypoxia-inducible factor prolyl hydroxylase inhibitors non-inferior to erythropoiesis-stimulating agents in chronic kidney diseaseAnaemia CKDLikely84%10
StableFinerenone reduces chronic kidney disease progression in type 2 diabetesFinerenone CKDLikely84%12
StableFinerenone reduces urine albumin-to-creatinine ratio in chronic kidney diseaseFinerenone CKDLikely83%12
StableLow bicarbonate predicts chronic kidney disease progressionMetabolic Acidosis CKDLikely80%10
StableFinerenone: cardiovascular events in diabetic chronic kidney diseaseFinerenone CKDLikely80%12
StableGLP-1 agonists cut cardiovascular events in chronic kidney diseaseGlp1 CKDLikely80%10
StableRenin-angiotensin-aldosterone system antiproteinuric effect beyond blood pressureRaas BlockadeLikely80%10
StableStatins reduce major adverse cardiovascular events in non-dialysis chronic kidney diseaseStatins CKDLikely80%9
StableHigh phosphate predicts cardiovascular death in chronic kidney diseaseCKD MBDLikely79%11
StableGLP-1 agonists reduce albuminuria in chronic kidney diseaseGlp1 CKDLikely79%10
StableDual renin-angiotensin-aldosterone system blockade increases chronic kidney disease harmRaas BlockadeLikely79%10
StableSGLT2 kidney outcomes in non-diabetic chronic kidney diseaseSglt2 CKDLikely79%12
StableRoxadustat for chronic kidney disease anaemia on dialysisAnaemia CKDLikely78%10
StableFinerenone beyond renin-angiotensin-aldosterone system blockade in chronic kidney diseaseFinerenone CKDLikely77%12
StableFinerenone plus SGLT2 inhibitors in chronic kidney diseaseFinerenone CKDLikely77%12
StableBlood pressure lowering reduces mortality in chronic kidney diseaseBlood Pressure CKDLikely76%10
StableVitamin D analogues reduce parathyroid hormone in chronic kidney diseaseCKD MBDLikely76%11
StableSGLT2 slows estimated glomerular filtration rate loss in advanced chronic kidney diseaseSglt2 CKDLikely76%12
StableHypoxia-inducible factor prolyl hydroxylase inhibitors improve iron utilisation in chronic kidney diseaseAnaemia CKDLikely75%10
StableStatins lower all-cause mortality in chronic kidney diseaseStatins CKDLikely75%9
StableSodium bicarbonate slows chronic kidney disease in acidosisMetabolic Acidosis CKDLikely73%10
StableIntensive blood pressure reduces cardiovascular events in chronic kidney diseaseBlood Pressure CKDLikely73%10
StableIntensive blood pressure lowers proteinuria in chronic kidney diseaseBlood Pressure CKDLikely73%10
StableSGLT2: cardiovascular death in chronic kidney diseaseSglt2 CKDLikely73%12
StableAlkali therapy preserves muscle mass in chronic kidney diseaseMetabolic Acidosis CKDLikely72%10
StableHyperuricaemia predicts chronic kidney disease progressionUric Acid CKDLikely72%10
StableSemaglutide slows estimated glomerular filtration rate decline in chronic kidney diseaseGlp1 CKDLikely71%10
StableNon-calcium binders lower mortality in chronic kidney diseaseCKD MBDUncertain63%11
StableGLP-1 agonists: direct kidney protectionGlp1 CKDUncertain63%10
StableIntensive blood pressure slows chronic kidney disease progressionBlood Pressure CKDUncertain61%10
StableLow-density lipoprotein below 70 reduces cardiovascular events in chronic kidney diseaseStatins CKDUncertain61%9
StableHigher serum bicarbonate slows chronic kidney diseaseMetabolic Acidosis CKDUncertain60%10
StableStatins: limited benefit in dialysis chronic kidney diseaseStatins CKDUncertain58%9
StableDietary acid reduction slows chronic kidney diseaseMetabolic Acidosis CKDUncertain56%10
StableIntensive blood pressure increases acute kidney injury risk in chronic kidney diseaseBlood Pressure CKDUncertain55%10
StableStopping angiotensin-converting enzyme inhibitors in advanced chronic kidney diseaseRaas BlockadeUncertain55%10
StableFinerenone in non-diabetic chronic kidney diseaseFinerenone CKDUncertain52%12
StableAllopurinol does not slow chronic kidney diseaseUric Acid CKDUncertain52%10
StableFebuxostat does not slow chronic kidney disease progressionUric Acid CKDUncertain48%10
StableUrate-lowering therapy reduces kidney failureUric Acid CKDUncertain44%10
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely65–84%Well supported, with some gaps or indirect evidence.
Uncertain40–64%Mixed or limited evidence. Genuinely open.
Doubtful15–39%Little support; the weight of evidence leans against it.
Refuted< 15%The evidence contradicts it — confidently false as stated.
Recent signal
strengthenedNew evidence raised the certainty since the last review.
weakenedNew evidence lowered the certainty since the last review.
newA claim added to the review recently.
StableNo recent change to the standing.
Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.
Update your priors.Track this topic